{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=71", "query": { "condition": "Lymphoma", "page": 71 }, "page_size": 10 }, "pagination": { "page": 71, "page_size": 10, "total_count": 5758, "total_pages": 576, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=72&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=70&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-01T02:22:29.623Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03239392", "title": "A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "LGL Leukemia", "CTCL" ], "interventions": [ { "name": "BNZ132-1-40", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bioniz Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2018-04-01", "completion_date": "2020-06-30", "has_results": false, "last_update_posted_date": "2021-05-25", "last_synced_at": "2026-11-01T02:22:29.623Z", "location_count": 4, "location_summary": "Duarte, California • Tampa, Florida • Columbus, Ohio + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03239392" }, { "nct_id": "NCT06079164", "title": "Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory Large B-cell Lymphoma" ], "interventions": [ { "name": "KITE-197", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2023-11-09", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-11-01T02:22:29.623Z", "location_count": 5, "location_summary": "Miami, Florida • Chicago, Illinois • Nashville, Tennessee + 2 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Austin", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06079164" }, { "nct_id": "NCT03934814", "title": "Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Lymphoma" ], "interventions": [ { "name": "TJ011133", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "I-Mab Biopharma US Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2019-04-16", "completion_date": "2023-01-10", "has_results": false, "last_update_posted_date": "2024-07-01", "last_synced_at": "2026-11-01T02:22:29.623Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • New Haven, Connecticut + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Lafayette", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03934814" }, { "nct_id": "NCT07810400", "title": "A Study Of Remote Patient Monitoring (RPM) Program For Cancer Patients Initiating Cancer-directed Therapy", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer", "Lymphoma" ], "interventions": [ { "name": "Smart Phone Application-based Intervention - SHIELD", "type": "BEHAVIORAL" }, { "name": "AION TempShield", "type": "OTHER" }, { "name": "Questionnaires", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 470, "start_date": "2026-11-15", "completion_date": "2031-06-30", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-11-01T02:22:29.623Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07810400" }, { "nct_id": "NCT05303792", "title": "Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B Acute Lymphoblastic Leukemia", "B Lymphoblastic Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Inotuzumab Ozogamicin", "type": "BIOLOGICAL" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 68, "start_date": "2023-06-09", "completion_date": "2029-05", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-11-01T02:22:29.623Z", "location_count": 71, "location_summary": "Birmingham, Alabama • Irvine, California • Orange, California + 60 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Irvine", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05303792" }, { "nct_id": "NCT04146571", "title": "Expanded Access to Ensartinib for Participants With ALK+ NSCLC", "overall_status": "AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Non-Small Cell Lung Cancer", "ALK Gene Rearrangement Positive" ], "interventions": [ { "name": "Ensartinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Xcovery Holdings, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2022-10-20", "last_synced_at": "2026-11-01T02:22:29.623Z", "location_count": 4, "location_summary": "Stanford, California • Bethesda, Maryland • Nashville, Tennessee + 1 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04146571" }, { "nct_id": "NCT01966809", "title": "Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Tumor, Recurrent" ], "interventions": [ { "name": "Photofrin photodynamic therapy.", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Harry T Whelan, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2015-06", "completion_date": "2017-12-19", "has_results": true, "last_update_posted_date": "2019-08-20", "last_synced_at": "2026-11-01T02:22:29.623Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01966809" }, { "nct_id": "NCT00301821", "title": "Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "epratuzumab", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2006-01", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2019-10-09", "last_synced_at": "2026-11-01T02:22:29.623Z", "location_count": 162, "location_summary": "Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 102 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00301821" }, { "nct_id": "NCT00782145", "title": "A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Neuroblastoma", "Ovarian Cancer", "Psychosocial Effects of Cancer and Its Treatment", "Sarcoma" ], "interventions": [ { "name": "educational intervention", "type": "OTHER" }, { "name": "informational intervention", "type": "OTHER" }, { "name": "internet-based intervention", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" }, { "name": "study of socioeconomic and demographic variables", "type": "OTHER" }, { "name": "survey administration", "type": "OTHER" }, { "name": "psychosocial assessment and care", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" }, { "name": "standard follow-up care", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Tufts Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Months", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Months to 18 Years" }, "enrollment_count": 198, "start_date": "2008-06", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2011-07-13", "last_synced_at": "2026-11-01T02:22:29.623Z", "location_count": 6, "location_summary": "Duarte, California • Boston, Massachusetts • Cincinnati, Ohio + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00782145" }, { "nct_id": "NCT00448357", "title": "Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "rabbit anti-thymocyte globulin (ATG)", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "methotrexate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 54, "start_date": "2005-10", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2017-07-17", "last_synced_at": "2026-11-01T02:22:29.623Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00448357" } ] }